Stay updated with breaking news from Denisea Yardley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.
Nearly 60% of health care providers surveyed failed to choose the same treatment strategies for HER2–early breast cancer.
Basel: Pharma major, Novartis, has announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival...
New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to